Clinical trial
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit…
NCT00278876 · Asan Medical Center, Other · Completed
Key facts
| NCT number | NCT00278876 |
|---|---|
| Title | Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation |
| Official title | Phase II Study of Imatinib Mesylate as Adjuvant Treatment in High-relapse Risk Localized Gastrointestinal Stromal Tumors With C-kit Mutation |
| Lead sponsor | Asan Medical Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma, Gastrointestinal Stromal Tumors |
| Intervention type | Drug |
| Interventions | Imatinib mesylate (Glivec) |
| Enrollment | 47 |
| Start date | Apr 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Mar 1, 2011 |
| First posted | Jan 19, 2006 |
| Last update posted | Jan 7, 2020 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: